Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy

Abstract This retrospective study evaluated the association of hyperreflective foci (HRF) with treatment response in diabetic macular oedema (DME) after anti-vascular endothelial growth factor (VEGF) therapy. The medical records, including of ophthalmologic examinations and optical coherence tomogra...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chu-Hsuan Huang, Chang-Hao Yang, Yi-Ting Hsieh, Chung-May Yang, Tzyy-Chang Ho, Tso-Ting Lai
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a8096c9a41954acbaee9bcf628c04c08
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a8096c9a41954acbaee9bcf628c04c08
record_format	dspace
spelling	oai:doaj.org-article:a8096c9a41954acbaee9bcf628c04c082021-12-02T15:53:59ZHyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy10.1038/s41598-021-84553-72045-2322https://doaj.org/article/a8096c9a41954acbaee9bcf628c04c082021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84553-7https://doaj.org/toc/2045-2322Abstract This retrospective study evaluated the association of hyperreflective foci (HRF) with treatment response in diabetic macular oedema (DME) after anti-vascular endothelial growth factor (VEGF) therapy. The medical records, including of ophthalmologic examinations and optical coherence tomography (OCT) images, of 106 patients with DME treated with either intravitreal ranibizumab or aflibercept were reviewed. The correlations between best-corrected visual acuity (BCVA) changes and HRF along with other OCT biomarkers were analysed. The mean logMAR BCVA improved from 0.696 to 0.461 after an average of 6.2 injections in 1 year under real-world conditions. Greater visual-acuity gain was noted in patients with a greater number of HRF in the outer retina at baseline (p = 0.037), along with other factors such as poor baseline vision (p < 0.001), absence of epiretinal membrane (p = 0.048), and presence of subretinal fluid at baseline (p = 0.001). The number of HRF after treatment was correlated with the presence of hard exudate (p < 0.001) and baseline haemoglobin A1C (p = 0.001). Patients with proliferative diabetic retinopathy had greater HRF reduction after treatment (p = 0.018). The number of HRF in the outer retina, in addition to other baseline OCT biomarkers, could be used to predict the treatment response in DME after anti-VEGF treatment.Chu-Hsuan HuangChang-Hao YangYi-Ting HsiehChung-May YangTzyy-Chang HoTso-Ting LaiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chu-Hsuan Huang Chang-Hao Yang Yi-Ting Hsieh Chung-May Yang Tzyy-Chang Ho Tso-Ting Lai Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy
description	Abstract This retrospective study evaluated the association of hyperreflective foci (HRF) with treatment response in diabetic macular oedema (DME) after anti-vascular endothelial growth factor (VEGF) therapy. The medical records, including of ophthalmologic examinations and optical coherence tomography (OCT) images, of 106 patients with DME treated with either intravitreal ranibizumab or aflibercept were reviewed. The correlations between best-corrected visual acuity (BCVA) changes and HRF along with other OCT biomarkers were analysed. The mean logMAR BCVA improved from 0.696 to 0.461 after an average of 6.2 injections in 1 year under real-world conditions. Greater visual-acuity gain was noted in patients with a greater number of HRF in the outer retina at baseline (p = 0.037), along with other factors such as poor baseline vision (p < 0.001), absence of epiretinal membrane (p = 0.048), and presence of subretinal fluid at baseline (p = 0.001). The number of HRF after treatment was correlated with the presence of hard exudate (p < 0.001) and baseline haemoglobin A1C (p = 0.001). Patients with proliferative diabetic retinopathy had greater HRF reduction after treatment (p = 0.018). The number of HRF in the outer retina, in addition to other baseline OCT biomarkers, could be used to predict the treatment response in DME after anti-VEGF treatment.
format	article
author	Chu-Hsuan Huang Chang-Hao Yang Yi-Ting Hsieh Chung-May Yang Tzyy-Chang Ho Tso-Ting Lai
author_facet	Chu-Hsuan Huang Chang-Hao Yang Yi-Ting Hsieh Chung-May Yang Tzyy-Chang Ho Tso-Ting Lai
author_sort	Chu-Hsuan Huang
title	Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy
title_short	Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy
title_full	Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy
title_fullStr	Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy
title_full_unstemmed	Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy
title_sort	hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a8096c9a41954acbaee9bcf628c04c08
work_keys_str_mv	AT chuhsuanhuang hyperreflectivefociinpredictingthetreatmentoutcomesofdiabeticmacularoedemaafterantivascularendothelialgrowthfactortherapy AT changhaoyang hyperreflectivefociinpredictingthetreatmentoutcomesofdiabeticmacularoedemaafterantivascularendothelialgrowthfactortherapy AT yitinghsieh hyperreflectivefociinpredictingthetreatmentoutcomesofdiabeticmacularoedemaafterantivascularendothelialgrowthfactortherapy AT chungmayyang hyperreflectivefociinpredictingthetreatmentoutcomesofdiabeticmacularoedemaafterantivascularendothelialgrowthfactortherapy AT tzyychangho hyperreflectivefociinpredictingthetreatmentoutcomesofdiabeticmacularoedemaafterantivascularendothelialgrowthfactortherapy AT tsotinglai hyperreflectivefociinpredictingthetreatmentoutcomesofdiabeticmacularoedemaafterantivascularendothelialgrowthfactortherapy
_version_	1718385468117090304

Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy

Ejemplares similares